Activity and outcomes of autologous stem cell transplantation in the private sector in Australia

Few Australasian autologous stem cell transplantation (ASCT) programmes perform ASCT in the private sector. Relatively little is known about ASCT outcomes in the private sector, which varies in care delivery models to the public system.

[1]  M. Perales,et al.  Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. , 2021, Blood advances.

[2]  D. Miklos,et al.  Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. , 2021, Transplantation and cellular therapy.

[3]  S. Harrison,et al.  Autologous stem cell transplantation in elderly multiple myeloma patients aged ≥65 years: a two‐centre Australian experience , 2021, Internal medicine journal.

[4]  I. Kerridge,et al.  Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study , 2020 .

[5]  N. Majhail,et al.  Expanding Access to Chimeric Antigen Receptor T-Cell Therapies: Challenges and Opportunities. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[6]  I. Irving,et al.  A 14‐year retrospective analysis of indications and outcomes of autologous haemopoietic stem cell transplantation in regional Queensland: a single‐centre experience , 2020, Internal medicine journal.

[7]  S. Sidana,et al.  CAR T-cell therapy: is it prime time in myeloma? , 2019, Blood advances.

[8]  M. Brouwers,et al.  Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review , 2019, The Journal of Frailty & Aging.

[9]  Nofisat Ismaila,et al.  Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  I. Turesson,et al.  Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival , 2018, European journal of haematology.

[11]  L. Xu,et al.  A review of hematopoietic cell transplantation in China: data and trends during 2008–2016 , 2017, Bone Marrow Transplantation.

[12]  M. Geyer,et al.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.

[13]  Y. Kodera,et al.  Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey , 2016, Bone Marrow Transplantation.

[14]  J. Szer,et al.  A Review of Hematopoietic Cell Transplantation in Australia and New Zealand, 2005 to 2013. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  H. Sørensen,et al.  The impact of comorbidity on cancer survival: a review , 2013, Clinical epidemiology.

[16]  T. Arneson,et al.  Costs of Autologous and Allogeneic Hematopoietic Cell Transplantation in the United States: A Study Using a Large National Private Claims Database , 2012, Bone Marrow Transplantation.

[17]  C. Critchley,et al.  The Medical Journal of Australia , 2008 .

[18]  T. Faunce,et al.  Private health insurance and regional Australia , 2005, The Medical journal of Australia.

[19]  J. Mackenbach,et al.  Widening socioeconomic inequalities in mortality in six Western European countries. , 2003, International journal of epidemiology.

[20]  Joseph Carolan,et al.  A costing study of blood and marrow transplantation services in NSW: final report , 2009 .